ASRS 2024: 72-Week results from the Phase 3 BALATON and COMINO trials
Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion
ASRS 2024: Sustainability expert panel demonstrates how retina specialists go green
This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD
ASRS 2024: Geographic atrophy, lesion growth and outer retinal tubulation
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy
What are attendees most looking forward to at this year's ASRS meeting?
Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting
ASRS 2024: Improving OCTA performance using AI and differential artery-vein analysis
Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"
Industry preview: Eye care companies announce presentations ahead of ASRS meeting
Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July
Alopecia areata and underlying corneal pathologies
Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata
Impact report highlights outcomes of Moorfields Eye Charity programmes
The organisation has secured £72.75 million for its new eye health centre
VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD
A novel formulation may prevent blood vessel growth and vascular leakage in the retina
Semaglutide may be associated with non-arteritic ischemic optic neuropathy (NAION)
GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific
Beacon Therapeutics announces new board members, funding to support XLRP and AMD programmes
The company has secured $170 million (approximately €157 million) in Series B funding
Preview: The American Society of Retina Specialists meets in Stockholm, Sweden
Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees
Visual and refractive outcomes of a combined opposite clear corneal incision procedure
Patients with corneal astigmatism underwent phacoemulsification and rotationally asymmetric multifocal IOL implantation
July is Dry Eye Awareness month: Resources from Prevent Blindness
Educational resources include handouts, videos and a dedicated webpage on the proper way to use eye drops
Altos Biologics submits EMA Marketing Authorisation Application for aflibercept biosimilar ALT-L9
Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea
EMA issues positive CHMP opinion for faricimab (Vabysmo) in third indication retinal vein occlusion
Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema
US FDA approves biosimilar aflibercept-mrbb (Ahzantive)
The drug is a biosimilar for aflibercept 2 mg (Eylea)
EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre) injection
Apellis will seek re-examination from the CHMP following the opinion
Insights into neovascular glaucoma: Pathogenesis and detection of diabetic retinopathy
Management of neovascular glaucoma focuses on decreasing retinal ischemia through panretinal photocoagulation and the injection of anti-VEGF agents
ASRS 2024: Industry updates and new research findings expected at this year's meeting
A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies
Post-hoc analyses of YOSEMITE/RHINE trials compare faricimab results to aflibercept
The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2
Inaugural Ramin Tadayoni Award will be granted at 2024 EURETINA Congress
The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research
Novel tactile bottle neck adaptor facilitates eye drop adherence for patients with visual impairment
The adaptor was tested by low-vision patients and participants with simulated visual impairment
RetinAI Discovery from Ikerian receives Class IIa MDR registration in EU
The diagnostic and monitoring tools use artificial intelligence-based models
Artificial intelligence as patient resource: findings from a chatbot investigation
Ophthalmologists graded AI bots' answers to questions from patients following cataract surgery
Aurion Biotech candidate AURN001 receives US Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation
The US Food and Drug Administration issued designations for the allogeneic cell therapy candidate, a therapeutic for corneal oedema
The 36th annual International Congress of German Ophthalmic Surgery (DOC) comes to Nuremberg
Sustainability, artificial intelligence and economic considerations are hot topics at this year’s meeting
Beacon Therapeutics treats first patient in global registration trial for X-linked retinitis pigmentosa therapeutic
XLRP often leads to blindness by middle age with no treatment options currently available
Paediatric case study suggests genetic syndrome link associated with ocular tumor
Investigators say the discovery highlights the importance of genetic consultation
Combining imaging modalities could enable earlier identification of diabetic retinopathy
The mapping method revealed prominent microscopic abnormalities consistent with DR